ArticleJACC. Advances2026
Left Atrial Volume as Predictor of Recurrence After Pulmonary Vein Isolation: A DECAAF II Substudy.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft atrial volume (LAV) is a known predictor of atrial arrhythmia (AA) recurrence after pulmonary vein isolation (PVI).
objectivesThe authors sought to assess the role of LAV in predicting AA recurrence and atrial fibrillation (AF) burden in patients with persistent AF (PerAF) undergoing PVI.
methodsThe DECAAF-II trial was a prospective randomized controlled trial of PerAF patients undergoing first-time ablation. Patients underwent late gadolinium-enhanced magnetic resonance imaging to calculate baseline LAV and baseline atrial fibrosis. Patients provided single-lead home electrocardiogram strips once daily and upon symptom onset. The primary endpoint was defined as freedom from recurrent AA following a 90-day blanking period through 365 days postprocedure. SMURDEN (Smartphone AF burden) was calculated by dividing the total number of days in AF by the total number of days when strips were sent. A covariate-adjusted Cox regression model was performed to identify independent predictors of success. Univariate and multivariate analysis was performed to predict SMURDEN beyond the 3-month blanking period.
resultsA total of 361 patients with 20.5% females and a mean age of 62 years were analyzed. Median LAV was 129 cc (IQR: 103.9-153.6). ROC analysis identified LAV <114 cc as the optimal cut point for success. In the Cox model, LAV <114 cc was the only significant independent predictor of procedural success with an HR of 0.53 (95% CI: 0.35-0.82, P = 0.04). A multivariate model of traditional risk factors accounted for 12% of the variability in SMURDEN (adjusted R
conclusionsIn patients with PerAF undergoing PVI as the first ablation procedure, LAV is a strong predictor of AA recurrence and SMURDEN. LAV larger than 114 cc was associated with more than a 40% risk of recurrent arrhythmia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.